What was Candel Therapeutics, Inc.'s revenue in Q1 FY2023?

Candel Therapeutics, Inc. reported total revenue of $102.0K in Q1 FY2023.

What was Candel Therapeutics, Inc.'s net profit in Q1 FY2023?

Candel Therapeutics, Inc. reported net profit of $-8.8M in Q1 FY2023, a net margin of -8622.5%.

What were Candel Therapeutics, Inc.'s margins in Q1 FY2023?

Candel Therapeutics, Inc. had operating margin of -9444.1% in Q1 FY2023.

What was Candel Therapeutics, Inc.'s EPS in Q1 FY2023?

Candel Therapeutics, Inc. reported diluted EPS of $-0.30 in Q1 FY2023.

Candel Therapeutics, Inc.CADLEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Deep Analysis

Candel Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing oncolytic immunotherapies for cancer treatment. Its product pipeline covers solid tumors and hematological malignancies, serving global oncology markets and addressing unmet medical needs for patients with limited treatment options.

Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022

Revenue

$102.0K

Gross Profit

N/A

Operating Profit

$-9.6M

Net Profit

$-8.8M

Gross Margin

N/A

Operating Margin

-9444.1%

Net Margin

-8622.5%

YoY Growth

229.0%

EPS

$-0.30

Candel Therapeutics, Inc. Q1 FY2023 Financial Summary

Candel Therapeutics, Inc. reported revenue of $102.0K (up 229.0% YoY) for Q1 FY2023, with a net profit of $-8.8M (down 906.3% YoY) (-8622.5% margin).

Key Financial Metrics

Total Revenue	$102.0K
Net Profit	$-8.8M
Gross Margin	N/A
Operating Margin	-9444.1%
Report Period	Q1 FY2023

Candel Therapeutics, Inc. Annual Revenue by Year

Candel Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $125.0K).

Year	Annual Revenue
2022	$125.0K	vs 2021 →

Candel Therapeutics, Inc. Quarterly Revenue & Net Profit History

Candel Therapeutics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

Quarter	Revenue	Revenue YoY	Net Profit	Net Margin
Q1 FY2023	$102.0K	+229.0%	$-8.8M	-8622.5%
Q4 FY2022	$32.0K	—	$-5.1M	-15884.4%
Q3 FY2022	$31.0K	+0.0%	$-8.7M	-28025.8%
Q2 FY2022	$31.0K	+0.0%	$-4.1M	-13383.9%
Q1 FY2022	$31.0K	—	$-874.0K	-2819.4%

Income Statement

	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023
Revenue	$31000	$31000	$31000	$32000	$102000
YoY Growth	N/A	0.0%	0.0%	N/A	229.0%

Balance Sheet

	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023
Assets	$101.6M	$93.3M	$85.0M	$77.7M	$67.2M
Liabilities	$37.8M	$33.2M	$32.9M	$30.0M	$27.6M
Equity	$63.8M	$60.1M	$52.1M	$47.7M	$39.7M

Cash Flow

	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023
Operating CF	$-8.1M	$-7.1M	$-9.4M	$-6.9M	$-10.8M